Clinical trial NCT05099094: VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases
Official title: A Safety and Efficacy Study of VEGFA-targeting Gene Therapy to Treat Refractory Retinal and Choroidal Neovascularization Diseases
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: EARLY_PHASE1
Conditions: Neovascular Age-related Macular Degeneration
Diabetic Macular Edema
Retinal Vein Occlusion
Keywords: Retinal diseases
Choroidal diseases
Neovascularization
nAMD
neovascular age-related macular degeneration
DME
Diabetic macular edema
RVO-ME
Retinal vein occlusion-Macular edema
Lead sponsor: Shanghai BDgene Co., Ltd.
Sponsor class: INDUSTRY
Collaborators: name: Eye & ENT Hospital of Fudan University
First posted: 2021-10-29
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Patients who respond to anti-VEGF therapy but with refractory retinal and choroidal neovascularization diseases including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion-Macular edema (RVO-ME).

Detailed description: Choroidal and retinal angiogenesis diseases are a group of diseases characterized by choroidal or retinal angiogenesis. These diseases are often correlated with the macular area, which may lead to significant visual loss. In this study, The IDLV vector is engineered to carry the VEGFA antibody gene. The gene is delivered to the RPE cells to express the VEGFA antibody which neutralizes the VEGFA activity in the posterior segment of the eye of individuals who have progressed to various forms of neovascular macular degeneration.

Eligibility criteria: Inclusion Criteria:

1. Patients with nAMD at the age ≥50; Or patients with diabetic macular edema (DME) at the age ≥18; Or patients with macular edema following retinal vein occlusion (RVO-ME) at the age ≥18.
2. Early Treatment Diabetic Retinopathy Study (ETDRS) best corrected visual acuity ≤63 and letter score ≥19 Corresponding Snellen vision ≤20/63 and ≥20/400).
3. OCT confirms the presence of intraretinal fluid or subretinal fluid in the fovea.
4. Have received anti-VEGF therapy in the past and have responded to anti-VEGF therapy.
5. With refractory conditions: repeated anti-VEGF treatments are required due to the disease condition. When the treatment is interrupted, the disease condition recurs (OCT examination indicates increased subretinal/inner effusion in the macula)
6. For patients with both eyes suffered, enroll the one with more severe condition.
7. Routine blood test, liver and kidney function, coagulation index of patients is normal：AST/ALT \< 2.5 × ULN; TB \< 1.5 × ULN; PT \< 1.5 × ULN; Hb \> 10 g/dL (male) and \> 9 g/dL (female); PLT \> 100 × 10\^3/µL; eGFR \> 30 mL/min/1.73 m\^2.

Subjects voluntarily join the study, sign an informed consent form, have good compliance, and cooperate with follow-up.

Exclusion Criteria:

1. Choroidal neovascularization or macular edema induced by other diseases.
2. Any other factors that affect vision improvement in the study eye, such as fibrosis, atrophy, or RPE tear in the fovea of the macula.
3. The study eye already has severe proliferative retinopathy, such as retinal neovascularization, traction retinal detachment, etc. (only for DME and RVO-ME patients) .
4. Retinal detachment or advanced glaucoma in the study eye.
5. Implants in the study eye (except intraocular lenses).
6. Received internal eye surgery within 3 months prior to enrollment.
7. Vitrectomy surgery on the study eye.
8. Received intravitreal glucocorticoid or other clinical research drugs (except anti-VEGF therapy) within 6 months prior to enrollment.
9. Myocardial infarction, cerebrovascular accident or transient ischemic attack occurred within 6 months prior to enrollment.
10. Poorly controlled hypertension under maximum medication (systolic blood pressure\>180 mmHg, diastolic blood pressure\>100 mmHg).
11. Poor blood glucose control under medication (fasting blood glucose is greater than or equal to 10.0 umol/L).
12. Women who are willing to give birth; pregnant/breastfeeding women Have received gene therapy in the past.

Primary outcomes:
measure: Treatment-related adverse events
timeFrame: At multiple timepoints after infusion up to 12 months.
Secondary outcomes:
measure: Changes in macular intraretinal fluid (IRF)
timeFrame: At multiple timepoints after infusion up to 12 months.
measure: Changes in subretinal fluid (SRF)
timeFrame: At multiple timepoints after infusion up to 12 months.
measure: Change in central retinal thickness (CRT)
timeFrame: At multiple timepoints after infusion up to 12 months.
measure: Changes in the area of choroidal neovascularization
timeFrame: At multiple timepoints after infusion up to 12 months.
measure: Changes in the area of fluorescein leakage
timeFrame: At multiple timepoints after infusion up to 12 months.
measure: The number of rescue treatments
timeFrame: At multiple timepoints after infusion up to 12 months.
measure: Evaluate the visual improvement
timeFrame: At multiple timepoints after infusion up to 12 months.
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Eye & ENT Hospital of Fudan University
state: Shanghai
Study officials:
affiliation: Eye & ENT Hospital of Fudan University
name: Gezhi Xu, Dr
role: STUDY_DIRECTOR
References: